Table of Content

1. Report Introduction

2. Mucopolysaccharidosis III Market Overview at a Glance
2.1. Market Share Distribution of Mucopolysaccharidosis III in 2018
2.2. Market Share Distribution of Mucopolysaccharidosis III in 2028

3. Disease Background and Overview: Mucopolysaccharidosis III
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Mucopolysaccharidosis III in 7MM
4.3. Total Prevalent Patient Population of Mucopolysaccharidosis III in 7MM – By Countries

5. Epidemiology of Mucopolysaccharidosis III by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Mucopolysaccharidosis III
5.1.3. Sub-Type Specific cases of the Mucopolysaccharidosis III *Indication Specific
5.1.4. Sex- Specific Cases of the Mucopolysaccharidosis III*Indication Specific
5.1.5. Diagnosed Cases of the Mucopolysaccharidosis III
5.1.6. Treatable Cases of the Mucopolysaccharidosis III
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Mucopolysaccharidosis III
5.4.3. Sub-Type Specific cases of the Mucopolysaccharidosis III*

5.4.4. Sex- Specific Cases of the Mucopolysaccharidosis III*

5.4.5. Diagnosed Cases of the Mucopolysaccharidosis III
5.4.6. Treatable Cases of the Mucopolysaccharidosis III
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Mucopolysaccharidosis III
5.5.3. Sub-Type Specific cases of the Mucopolysaccharidosis III*

5.5.4. Sex- Specific Cases of the Mucopolysaccharidosis III*

5.5.5. Diagnosed Cases of the Mucopolysaccharidosis III
5.5.6. Treatable Cases of the Mucopolysaccharidosis III
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Mucopolysaccharidosis III
5.6.3. Sub-Type Specific cases of the Mucopolysaccharidosis III*

5.6.4. Sex- Specific Cases of the Mucopolysaccharidosis III*

5.6.5. Diagnosed Cases of the Mucopolysaccharidosis III
5.6.6. Treatable Cases of the Mucopolysaccharidosis III
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Mucopolysaccharidosis III
5.7.3. Sub-Type Specific cases of the Mucopolysaccharidosis III*

5.7.4. Sex- Specific Cases of the Mucopolysaccharidosis III*

5.7.5. Diagnosed Cases of the Mucopolysaccharidosis III
5.7.6. Treatable Cases of the Mucopolysaccharidosis III
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Mucopolysaccharidosis III
5.8.3. Sub-Type Specific cases of the Mucopolysaccharidosis III*

5.8.4. Sex- Specific Cases of the Mucopolysaccharidosis III*

5.8.5. Diagnosed Cases of the Mucopolysaccharidosis III
5.8.6. Treatable Cases of the Mucopolysaccharidosis III
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Mucopolysaccharidosis III
5.9.3. Sub-Type Specific cases of the Mucopolysaccharidosis III*

5.9.4. Sex- Specific Cases of the Mucopolysaccharidosis III*

5.9.5. Diagnosed Cases of the Mucopolysaccharidosis III
5.9.6. Treatable Cases of the Mucopolysaccharidosis III

6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Unmet Needs of the Mucopolysaccharidosis III

8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile

9. Pipeline Therapies – At a glance

10. Key Cross Competition

11. Emerging Therapies for Mucopolysaccharidosis III
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile

12. Mucopolysaccharidosis III: 7MM Market Analysis
12.1. 7MM Market Size of Mucopolysaccharidosis III
12.2. 7MM Percentage Share of drugs marketed for Mucopolysaccharidosis III
12.3. 7MM Market Sales of Mucopolysaccharidosis III by Products

13. Mucopolysaccharidosis III: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Mucopolysaccharidosis III in United States
13.1.2. Percentage Share of drugs marketed for Mucopolysaccharidosis III in United States
13.1.3. Market Sales of Mucopolysaccharidosis III by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Mucopolysaccharidosis III in Germany
13.2.1.2. Percentage Share of drugs marketed for Mucopolysaccharidosis III in Germany
13.2.1.3. Market Sales of Mucopolysaccharidosis III by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Mucopolysaccharidosis III in France
13.2.2.2. Percentage Share of drugs marketed for Mucopolysaccharidosis III in France
13.2.2.3. Market Sales of Mucopolysaccharidosis III by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Mucopolysaccharidosis III in Italy
13.2.3.2. Percentage Share of drugs marketed for Mucopolysaccharidosis III in Italy
13.2.3.3. Market Sales of Mucopolysaccharidosis III by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Mucopolysaccharidosis III in Spain
13.2.4.2. Percentage Share of drugs marketed for Mucopolysaccharidosis III in Spain
13.2.4.3. Market Sales of Mucopolysaccharidosis III by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Mucopolysaccharidosis III in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Mucopolysaccharidosis III in United Kingdom
13.2.5.3. Market Sales of Mucopolysaccharidosis III by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Mucopolysaccharidosis III in Japan
13.3.2. Percentage Share of drugs marketed for Mucopolysaccharidosis III in Japan
13.3.3. Market Sales of Mucopolysaccharidosis III by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight



List of Figures


Figure 1: Total Prevalent/Incident Cases of the Mucopolysaccharidosis III in 7MM
Figure 2: Total Prevalent/Incident Cases of the Mucopolysaccharidosis III in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Mucopolysaccharidosis III in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Mucopolysaccharidosis III in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Mucopolysaccharidosis III in United States (2017-2028)
Figure 6: Diagnosed Cases of the Mucopolysaccharidosis III in United States (2017-2028)
Figure 7: Treatable Cases of the Mucopolysaccharidosis III in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Mucopolysaccharidosis III in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Mucopolysaccharidosis III in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Mucopolysaccharidosis III in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Mucopolysaccharidosis III in Germany (2017-2028)
Figure 12: Treatable Cases of the Mucopolysaccharidosis III in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Mucopolysaccharidosis III in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Mucopolysaccharidosis III in France (2017-2028)
Figure 15: Sex- Specific Cases of the Mucopolysaccharidosis III in France (2017-2028)
Figure 16: Diagnosed Cases of the Mucopolysaccharidosis III in France (2017-2028)
Figure 17: Treatable Cases of the Mucopolysaccharidosis III in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Mucopolysaccharidosis III in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Mucopolysaccharidosis III in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Mucopolysaccharidosis III in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Mucopolysaccharidosis III in Italy (2017-2028)
Figure 22: Treatable Cases of the Mucopolysaccharidosis III in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Mucopolysaccharidosis III in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Mucopolysaccharidosis III in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Mucopolysaccharidosis III in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Mucopolysaccharidosis III in Spain (2017-2028)
Figure 27: Treatable Cases of the Mucopolysaccharidosis III in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Mucopolysaccharidosis III in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Mucopolysaccharidosis III in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Mucopolysaccharidosis III in UK (2017-2028)
Figure 31: Diagnosed Cases of the Mucopolysaccharidosis III in UK (2017-2028)
Figure 32: Treatable Cases of the Mucopolysaccharidosis III in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Mucopolysaccharidosis III in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Mucopolysaccharidosis III in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Mucopolysaccharidosis III in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Mucopolysaccharidosis III in Japan (2017-2028)
Figure 37: Treatable Cases of the Mucopolysaccharidosis III in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Figure 42:7MM- Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Figure 45: United States-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Figure 48: Germany-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Figure 51: France-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Figure 54: Italy-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Figure 57: Spain-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Figure 60:UK-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Figure 63: Japan-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)


List of Tables


Table 1: Total Prevalent/Incident Cases of the Mucopolysaccharidosis III in 7MM
Table 2: Total Prevalent/Incident Cases of the Mucopolysaccharidosis III in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Mucopolysaccharidosis III in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Mucopolysaccharidosis III in United States (2017-2028)
Table 5: Sex- Specific Cases of the Mucopolysaccharidosis III in United States (2017-2028)
Table 6: Diagnosed Cases of the Mucopolysaccharidosis III in United States (2017-2028)
Table 7: Treatable Cases of the Mucopolysaccharidosis III in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Mucopolysaccharidosis III in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Mucopolysaccharidosis III in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Mucopolysaccharidosis III in Germany (2017-2028)
Table 11: Diagnosed Cases of the Mucopolysaccharidosis III in Germany (2017-2028)
Table 12: Treatable Cases of the Mucopolysaccharidosis III in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Mucopolysaccharidosis III in France (2017-2028)
Table 14: Sub-Type Specific cases of the Mucopolysaccharidosis III in France (2017-2028)
Table 15: Sex- Specific Cases of the Mucopolysaccharidosis III in France (2017-2028)
Table 16: Diagnosed Cases of the Mucopolysaccharidosis III in France (2017-2028)
Table 17: Treatable Cases of the Mucopolysaccharidosis III in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Mucopolysaccharidosis III in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Mucopolysaccharidosis III in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Mucopolysaccharidosis III in Italy (2017-2028)
Table 21: Diagnosed Cases of the Mucopolysaccharidosis III in Italy (2017-2028)
Table 22: Treatable Cases of the Mucopolysaccharidosis III in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Mucopolysaccharidosis III in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Mucopolysaccharidosis III in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Mucopolysaccharidosis III in Spain (2017-2028)
Table 26: Diagnosed Cases of the Mucopolysaccharidosis III in Spain (2017-2028)
Table 27: Treatable Cases of the Mucopolysaccharidosis III in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Mucopolysaccharidosis III in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Mucopolysaccharidosis III in UK (2017-2028)
Table 30: Sex- Specific Cases of the Mucopolysaccharidosis III in UK (2017-2028)
Table 31: Diagnosed Cases of the Mucopolysaccharidosis III in UK (2017-2028)
Table 32: Treatable Cases of the Mucopolysaccharidosis III in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Mucopolysaccharidosis III in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Mucopolysaccharidosis III in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Mucopolysaccharidosis III in Japan (2017-2028)
Table 36: Diagnosed Cases of the Mucopolysaccharidosis III in Japan (2017-2028)
Table 37: Treatable Cases of the Mucopolysaccharidosis III in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Table 42:7MM- Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Table 45: United States-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Table 48: Germany-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Table 51: France-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Table 54: Italy-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Table 57: Spain-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Table 60:UK-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Mucopolysaccharidosis III in USD MM (2017-2028)
Table 63: Japan-Market Share Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Mucopolysaccharidosis III by Therapies in USD MM (2017-2028)